			Double-blind Placebo-controlled Treatment Period: 24 weeks (with open-label insulin/existing OAD therapies) Group A: placebo + insulin Group B: DAPA 2.5 mg daily + insulin Group C: DAPA 5 mg daily + insulin Group D: DAPA 10 mg daily + insulin Double-blind Extension Period I: 24 weeks Double-blind Extension Period II: 56 weeks	DAPA 5 mg	8.62 ± 0.89	−0.89	−0.49^*
				(N = 211)			(−0.65, −0.34)
				DAPA 10 mg	8.57 ± 0.82	−0.96	−0.57^*
				(N = 194)			(−0.72, −0.42)
				^*p < 0.001 vs. PBO
					FPG (mg/dL) at 24 Weeks
					Baseline Mean ± SD	Adjusted Mean Change (95% CI)	Difference vs. PBO
				PBO	170.6 ± 57.2	-	-
				(N = 193)
				DAPA 2.5 mg	180.1 ± 59.9	−11.71^*	-
				(N = 202)		(−21.4, −2.0)
				DAPA 5 mg	185.4 ± 58.7	−20.18^*	-
				(N = 211)		(−29.9, −10.6)
				DAPA 10 mg	173.1 ± 54.9	−19.82^*	-
				(N = 194)		(−29.6, −10.1)
				^*p < 0.001 vs. baseline
					Body Weight (kg) at 24 Weeks
					Baseline Mean ± SD	Adjusted Mean Change	Difference vs. PBO (95% CI)
				PBO	94.5 ± 19.8	0.43	-
				(N = 193)
				DAPA 2.5 mg	93.0 ± 16.7	−0.92	−1.35^*
				(N = 202)			(−1.90, −0.80)
				DAPA 5 mg	93.3 ± 17.4	−1	−1.42^*
				(N = 211)			(−1.97, −0.88)
				DAPA 10 mg	94.5 ± 16.8	−1.61	−2.04^*
				(N = 194)			(−2.59, −1.48)
				^*p < 0.001 vs. PBO
					HbA1C (%) at 48 Weeks
					Baseline Mean ± SD	Adjusted Mean Change	Difference vs. PBO (95% CI)
				PBO	8.47 ± 0.77	−0.47	-
				(N = 193)
				DAPA 2.5 mg	8.46 ± 0.78	−0.79	−0.32^*
				(N = 202)			(−0.48, −0.16)
				DAPA 5 mg	8.62 ± 0.89	−0.96	−0.49^*
				(N = 211)			(−0.65, −0.33)
				DAPA 10 mg	8.57 ± 0.82	−1.01	−0.54^*
				(N = 194)			(−0.70, −0.38)
				^*p < 0.001 vs. PBO
					FPG (mg/dL) at 48 Weeks